Furthermore, a systematic understanding is lacking regarding the prevalence of PIK3CA mutations in HR+/HER2- advanced/unresectable or metastatic breast cancer or within clinically relevant molecular BC subgroups. The gene discussed is PIK3CA; the disease is breast cancer.